AAIC Investment Pte. Ltd. (Headquarters: Singapore; Representative: Susumu Tsubaki; hereinafter referred to as “AAIC Investment”) has invested in DeepEcho (Headquarters: Morocco; CEO: Youssef Bouyakhf) through the Africa Innovation & Healthcare Fund II (hereinafter referred to as “AHF2”), an investment fund specializing in the healthcare sector in Africa.

DeepEcho develops and provides an AI-powered fetal ultrasound analysis platform. The company also received 510(k) * clearance from the U.S. Food and Drug Administration (FDA) in June 2025. The company has announced that its AI has achieved a recognition accuracy of over 95% at the clinical level, demonstrating that it has the same reliability as experienced medical professionals. This approval not only allows the product to be sold and introduced in the U.S. market but also means that the safety and effectiveness of the technology have been recognized internationally. This will be an important milestone in the future for the spread of the technology in the Global South, including Africa, where there is a shortage of medical personnel.

DeepEcho ‘s AI technology automatically recognizes and classifies ultrasound images of fetal head, abdomen, amniotic fluid, and other parts of the fetus in real time, instantly identifying the “standard views” required for diagnosis. It uses the world’s largest collection of fetal ultrasound image data for learning, helping doctors improve the accuracy of their diagnoses and streamline their work. In addition, segmentation processing, which clearly distinguishes structures, enables more standardized analysis.

The company has been highly acclaimed internationally, having been selected for the Google-sponsored startup accelerator “AI First MENA & Turkey.” In addition to the standard view recognition and automatic analysis functions currently offered, the next-generation technology aims to use AI to identify new biomarkers and to predict complex pregnancy complications such as preeclampsia at an early stage. This is expected to lead to early medical intervention and improved maternal and child health.

The company is also actively seeking opportunities to collaborate with Japanese companies, and its CEO plans to visit Japan to coincide with the Tokyo International Conference on African Development (TICAD), which will be held in Yokohama in August 2025.

Demo photo: provided by the company

* Prior notification system for the U.S. Food and Drug Administration (FDA) to approve the sale of medical devices. Section 510(k) of the Food, Drug, and Cosmetic Act

[Company Overview]

● DeepEcho
name: DeepEcho
location: Morocco

Representative: Youssef Bouyakhf , Co-founder & CEO

URL: https://deepecho.io/

Business description:Deepecho develops AI-based solutions to support fetal ultrasound examinations. It aims to help medical professionals measure fetuses and detect abnormalities accurately and efficiently, thereby resolving the issue of access to medical care.

●AAIC Investment
name: AAIC Investment Pte. Ltd.
location: Singapore

Representative: Susumu Tsubaki

Founded: 2013

URL:https : //aaicinvestment.com

Business description: Established in Singapore in 2013 as a fund management company for
AAIC Holdings. Since 2014, has supported the management of CVC (corporate venture capital) for Japanese companies. In 2017, the first Japanese fund specializing in Africa (Africa Healthcare Fund, AHF No. 1) was established, and investments were mainly made in the African healthcare sector. In 2022, the Africa Innovation & Healthcare Fund (AHF No. 2) was established, and the first closing was held at the end of March 2022. The number of companies invested in through both funds is 60 (as of June 2025).

For queries related to this press release
AAIC Investment Pte. Ltd.
Hiroki ISHIDA
Representative of Kenya office and Director of Egypt Office
pr-investment@ aa-ic.com
(Please remove the space behind@ when enquiring via email)